<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy&lt;sup&gt;*&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy<sup>*</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy<sup>*</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2">Intensive phase</td> <td class="subtitle1" colspan="2">Continuation phase</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Drugs</td> <td class="subtitle2">Interval and doses<sup>¶</sup><br/> minimal duration</td> <td class="subtitle2">Drugs</td> <td class="subtitle2">Interval and doses<sup>¶Δ</sup><br/> minimal duration</td> </tr> <tr> <td colspan="4"><strong>Regimen 1:</strong> Preferred regimen for HIV-infected adults with newly diagnosed tuberculosis</td> </tr> <tr> <td class="indent1">INH</td> <td class="divider_bottom" rowspan="4"> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>◊</sup></td> <td class="divider_bottom" rowspan="4">INH/RIF</td> <td class="divider_bottom" rowspan="4"> <p>7 days per week for 126 doses (18 weeks), or</p> 5 days per week for 90 doses (18 weeks)<sup>◊</sup></td> </tr> <tr> <td class="indent1">RIF</td> </tr> <tr> <td class="indent1">PZA</td> </tr> <tr class="divider_bottom"> <td class="indent1">EMB</td> </tr> <tr> <td colspan="4"><strong>Regimen 2:</strong> Alternative regimen for HIV-infected adults in setting of resistance or intolerance to PZA</td> </tr> <tr> <td class="indent1">INH</td> <td rowspan="3"> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>◊</sup></td> <td rowspan="3">INH/RIF</td> <td rowspan="3"> <p>7 days per week for 217 doses (31 weeks), or</p> 5 days per week for 155 doses (31 weeks)<sup>◊</sup></td> </tr> <tr> <td class="indent1">RIF</td> </tr> <tr> <td class="indent1">EMB</td> </tr> </tbody></table></div><div class="graphic_lgnd">NOTE: If rifampin is replaced with rifabutin, refer to UpToDate table on rifabutin and antiretroviral therapy for dosing recommendations.</div><div class="graphic_footnotes"><p>DOT: directly observed therapy; EMB: ethambutol; INH: isoniazid; PZA: pyrazinamide; RIF: rifampin.</p>
<p>* For HIV-infected patients who are not receiving antiretroviral therapy, the continuation phase should be extended by three months (or 90 doses) for regimen 1 (above) and for at least three months for regimen 2.<sup>[1]</sup></p>
<p>¶ When DOT is used, drugs may be given five days/week, and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice.</p>
<p>Δ To help evaluate treatment effectiveness, sputum smears and mycobacterial cultures should be obtained at least monthly until at least two sequential cultures are negative and the patient is responding clinically to antituberculous therapy. Patients treated with regimen 1 with positive cultures at completion of two months of therapy should receive a seven-month (31-week; 217 doses [daily]) continuation phase; those receiving regimen 2 without PZA should probably have their continuation phase extended by three months as well (one year total). Patients with a positive sputum culture after three months of therapy should be evaluated for possible treatment failure.<sup>[1]</sup></p>
◊ Five-day-a-week administration is always given by DOT.</div><div class="graphic_reference">Reference:
<ol>
<li>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</li>
</ol>
<p class="extra_spacing_top">Data from:</p>
<ol>
<li>Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America 2023. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a> (Accessed on October 26, 2023).</li>
</ol></div><div id="graphicVersion">Graphic 58653 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
